Spyre Therapeutics Inc

SYRE

45.410USD

-2.110-4.44%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

Spyre Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

54 / 391

Overall Ranking

161 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Spyre Therapeutics Inc Highlights

StrengthsRisks

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

Undervalued

The company’s latest PE is -19.53, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 66.99M shares, decreasing 8.25% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 120.48K shares of this stock.

Analyst Rating

Based on 15 analysts

Strong Buy

Current Rating

60.786

Target Price

+27.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Spyre Therapeutics Inc is 5.19, ranking 376 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.19

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Spyre Therapeutics Inc is 5.85, ranking 356 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -19.53, which is -114.97% below the recent high of 2.92 and -0.44% above the recent low of -19.61.

Score

Industry at a Glance

Previous score

5.85

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 54/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Spyre Therapeutics Inc is 9.20, ranking 10 out of 391 in the Biotechnology & Medical Research industry. The average price target is 49.00, with a high of 70.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

9.20

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Spyre Therapeutics Inc is 9.39, ranking 9 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 51.62 and the support level at 40.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.45

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Spyre Therapeutics Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 86.34%, representing a quarter-over-quarter increase of 1.23%. The largest institutional shareholder is The Vanguard, holding a total of 4.02M shares, representing 5.12% of shares outstanding, with 6.95% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

8.97M

+4.22%

BlackRock Institutional Trust Company, N.A.

3.59M

+0.23%

RTW Investments L.P.

3.62M

--

The Vanguard Group, Inc.

Star Investors

3.04M

-0.52%

Fairmount Funds Management LLC

4.02M

--

VR Adviser, LLC

2.69M

--

Deutsch (Peter E)

3.55M

+825.37%

Capital International Investors

2.39M

--

Perceptive Advisors LLC

1.23M

-19.61%

Driehaus Capital Management, LLC

2.06M

-1.21%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Spyre Therapeutics Inc is 4.84, ranking 66 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 3.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Spyre Therapeutics Inc

SYRE

7.08 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment